Idera Pharmaceuticals, Inc.

356 articles with Idera Pharmaceuticals, Inc.

• Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/9/2021

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2021.

• Idera Pharmaceuticals Announces Corporate Updates

  5/18/2021

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company’s trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, to its overall survival (OS) primary endpoint.

• Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

  4/29/2021

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2021.

• 

  Idera’s Melanoma Candidate Hits Snag in Phase III Trial

  3/19/2021

  A Phase III trial from Idera Pharmaceuticals did not reach the primary endpoint of ORR in patients with anti-PD-1 refractory advanced melanoma treated with a combination regimen comprising ipilimumab and the company’s investigational agent tilsotolimod.

• Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma– Objective Response Rate Endpoint Not Met –

  3/18/2021

  Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate (ORR)

• Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateILLUMINATE-301 Continues on Track for Data Later this Month

  3/1/2021

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020.

• Idera Pharmaceuticals to Present at Upcoming Conferences - Jan 11, 2021

  1/11/2021

  Idera Pharmaceuticals, Inc. announced that it will provide a company outlook for 2021 at upcoming conferences.

• Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million

  12/15/2020

  Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the “Purchase Agreement”), resulting in aggregate proceeds of up to $20.7 million in common stock and warrant investment by funds affiliated with an institutional investor.

• Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer

  11/17/2020

  Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; “Idera”) today announced that Daniel Soland will join Idera on January 4, 2021, as Senior Vice President and Chief Operating Officer (COO).

• Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate UpdateILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances

  10/29/2020

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2020. “Tilsotolimod is the most advanced TLR-9 agonist therapy in development, and we have made tremendous strides against our objectives for 2020,” stated Vincent Milano, Idera’s Chief Executive Officer. “We continue to work diligently against our timelines for ILLUMINATE-301, which

• Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037– Protects Method-of-Use in CRC and HNSCC –

  9/28/2020

  Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907 Patent) and allowed U.S. Patent Application No. 16/557,597 (the ‘597 Application), both entitled “Immune Modulation with TLR9 Agonists for Cancer Treatment” and each of which includes the Company’s investigational therapy tilsotolimod.

• Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020

  9/15/2020

  Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presented AbbVie to present a trial-in-progress poster of ABBV-368 in combination with tilsotolimod in recurrent / metastatic head and neck squamous cell carcinoma (HNSCC) Idera also to present at H.C. Wainwright 22nd Annual Global Investment Conference EXTON, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA)

• Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate UpdateEnhanced Financial Flexibility as ILLUMINATE-301 Continues on Track

  8/4/2020

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2020.

• Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million

  7/15/2020

  Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to which Idera has sold shares of common stock (or common stock equivalents), together with accompanying warrants to purchase an additional shares of common stock, for aggregate gross pr

• Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer

  6/2/2020

  Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of  ILLUMINATE-206, a Phase 2, open-label, multi-center study to evaluate tilsotolimod in combination with Opdivo® (nivolumab) and Yervoy®* (ipilimumab) in immunotherapy-naive micro-satellite stable colorectal cancer (MSS-CRC) patients. Based on data to date, the Company plans to expand the study to further eval

• Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders2020 Annual Meeting of Stockholders will be held in a virtual format 

  5/1/2020

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today provided notice of a change in the location for its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) via the filing of additional proxy materials with the U.S. Securities and Exchange Commission. Due to the public health impact of the coronavirus (COVID-19) pandemic and related government actions, and to support the health and well-being of our employees, stockho

• Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate UpdateFinancial Resources Through Critical Catalyst of Phase 3 ORR Readout and Potentially Beyond

  4/30/2020

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2020.

• Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020

  4/23/2020

  Idera Pharmaceuticals, Inc. announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 agonist, will be presented at the American Association for Cancer Research Virtual Annual Meeting I, to be held April 27-28, 2020, as part of a “Clinical Trial Poster Session.”.

• Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma

  4/21/2020

  – Overall response rate of 22% – – Disease control rate of 71% – – Median overall survival of 21 months – – Key topline data from ILLUMINATE-301 expected in Q1 2021 –

• Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million

  4/7/2020

  Idera Pharmaceuticals, Inc. announced entering into an agreement with a fund affiliated with an institutional investor providing for a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to which Idera has sold shares of common stock together with accompanying warrants to purchase an additional shares of common stock, for aggregate gross proceeds of $5.0 million.